CoChat
Sign Up
Cited by 232

Mammalian cell culture for production of recombinant proteins: a review of the critical steps in their biomanufacturing

O’Flaherty, Róisín, Bergin, Adam, Flampouri, Evangelia, Mota, Letícia Martins, Obaidi, Ismael, Quigley, Andrew, Xie, Yongjing, Butler, Michael·2020·Biotechnology Advances
DOI 10.1016/j.biotechadv.2020.107552
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biotechadv.2020.107552

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recombinant proteins, including growth factors, may exhibit batch-to-batch variability arising from differences in expression systems, host cell biology, post-translational modifications or manufacturing conditions.

    “Recombinant proteins, including growth factors, may also exhibit batch-to-batch variability arising from differences in expression systems, host cell biology, post-translational modifications or manufacturing conditions (O'Flaherty et al., 2020; Wang et al., 2025).”

    From Challenges and solutions in transitioning to animal-free standards: a comprehensive analysis of components in human cell-based developmental neurotoxicity assays (2026) · cites this paper as O'Flaherty et al., 2020

    Section 3.1 (p. 8) says recombinant-protein product consistency depends on controlled culture conditions and that changes in those conditions can alter protein quality, including glycosylation. Sections 2 and 2.4 (pp. 3, 7) also link expression-system choice to post-translational modifications. The review supports the general possibility of manufacturing-related variability, but it does not specifically establish batch-to-batch variability in recombinant growth factors. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 186

  1. Adamson, L., Walum, E., 2007. Insulin and IGF-1 mediated inhibition of apoptosis in CHO cells grown in suspension in a protein-free medium. Alternat. Lab. Anim. ATLA 35 (3), 349 -352. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0005)
  2. Alekseychyk, L., Su, C., Becker, G.W., Treuheit, M.J., Razinkov, V.I., 2017. Highthroughput screening and analysis of charge variants of monoclonal antibodies in multiple formulations. SLAS Discov. Adv. Life Sci. R & D 22 (8), 1044 -1052. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0010)
  3. Andersen, D.C., Krummen, L., 2002. Recombinant protein expression for therapeutic applications. Curr. Opin. Biotechnol. 13 (2), 117 -123. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0015)
  4. Androulla, M.N., Lefkothea, P.C., 2018. CAR T-cell therapy: A new era in cancer immunotherapy. Curr. Pharm. Biotechnol. 19 (1), 5 -18. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0020)
  5. Arora, M., 2013. Cell culture media: A review. Mater. Methods 3, 175. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0030)
  6. Astori, G., Amati, E., Bambi, F., Bernardi, M., Chieregato, K., Schäfer, R., Sella, S., Rodeghiero, F., 2016. Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: Present and future. Stem Cell Res. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0035)
  7. Backliwal, G., Hildinger, M., Hasija, V., Wurm, F.M., 2008a. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol. Bioeng. 99 (3), 721 -727. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0040)
  8. Backliwal, G., Hildinger, M., Kuettel, I., Delegrange, F., Hacker, D.L., Wurm, F.M., 2008b. Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol. Bioeng. 101 (1), 182 -189. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0045)
  9. Baek, E., Kim, C.L., Kim, M.G., Lee, J.S., Lee, G.M., 2016. Chemical inhibition of autophagy: Examining its potential to increase the speci fi c productivity of recombinant CHO cell lines. Biotechnol. Bioeng. 113 (9), 1953 -1961. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0050)
  10. Bandaranayake, A.D., Almo, S.C., 2014. Recent advances in mammalian protein production. FEBS Lett. 588 (2), 253 -260. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0055)
  11. Barr, I.G., Donis, R.O., Katz, J.M., McCauley, J.W., Odagiri, T., Trusheim, H., Tsai, T.F., Wentworth, D.E., 2018. Cell culture-derived in fl uenza vaccines in the severe 2017 -2018 epidemic season: A step towards improved in fl uenza vaccine e ff ectiveness. NPJ Vacc. 3 (1), 44. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0060)
  12. Barry, C.E., Matter, A., 2006. Next-generation therapeutics - Turning the current ' innovation gap ' into an ' innovation leap ' . Curr. Opin. Chem. Biol. 10 (4), 291 -293. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0065)
  13. Bauman, E., Granja, P.L., Barrias, C.C., 2018. Fetal bovine serum-free culture of endothelial progenitor cells -progress and challenges. J. Tissue Eng. Regen. Med. 12 (7), 1567 -1578. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0070)
  14. Bertolini, L.R., Meade, H., Lazzarotto, C.R., Martins, L.T., Tavares, K.C., Bertolini, M., Murray, J.D., 2016. The transgenic animal platform for biopharmaceutical production. Transgen. Res. 25 (3), 329 -343. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0075)
  15. Bibila, T.A., Robinson, D.K., 1995. In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol. Prog. 11 (1), 1 -13. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0080)
  16. Birch, J.R., Racher, A.J., 2006. Antibody production. Adv. Drug Deliv. Rev. 58 (5), 671 -685.
  17. Braasch, K., Nikolic-Jaric, M., Cabel, T., Salimi, E., Bridges, G.E., Thomson, D.J., Butler, M., 2013. The changing dielectric properties of CHO cells can be used to determine early apoptotic events in a bioprocess. Biotechnol. Bioeng. 110 (11), 2902 -2914. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0090)
  18. Brindley, D.A., Davie, N.L., Culme-Seymour, E.J., Mason, C., Smith, D.W., Rowley, J.A., 2012. Peak serum: Implications of serum supply for cell therapy manufacturing. Regen. Med. 7. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0095)
  19. Brinson, R.G., Marino, J.P., Delaglio, F., Arbogast, L.W., Evans, R.M., Kearsley, A., Gingras, G., Ghasriani, H., Aubin, Y., Pierens, G.K., Jia, X., Mobli, M., Grant, H.G., Keizer, D.W., Schweimer, K., Stahle, J., Widmalm, G., Zartler, E.R., Lawrence, C.W., Reardon, P.N., Cort, J.R., Xu, P., Ni, F., Yanaka, S., Kato, K., Parnham, S.R., Tsao, D., Blomgren, A., Rundlof, T., Trielo ff , N., Schmieder, P., Ross, A., Skidmore, K., Chen, K., Keire, D., Freedberg, D.I., Suter-Stahel, T., Wider, G., Ilc, G., Plavec, J., Bradley, S.A., Baldisseri, D.M., Sforca, M.L., Zeri, A.C.M., Wei, J.Y., Szabo, C.M., Amezcua, C.A., Jordan, J.B., Wikstrom, M., 2019. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. mAbs 11 (1), 94 -105. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0100)
  20. Bunting, S., Zhang, L., Xie, L., Bullens, S., Mahimkar, R., Fong, S., Sandza, K., Harmon, D., Yates, B., Handyside, B., Sihn, C.R., Galicia, N., Tsuruda, L., O'Neill, C.A., Bagri, A., Colosi, P., Long, S., Vehar, G., Carter, B., 2018. Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice. Mol. Ther. 26 (2), 496 -509. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0105)
  21. Butler, M., 2005. Animal cell cultures: Recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 68 (3), 283 -291. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0110)
  22. Cadena-Herrera, D., Esparza-De Lara, J.E., Ramírez-Ibañez, N.D., López-Morales, C.A., Pérez, N.O., Flores-Ortiz, L.F., Medina-Rivero, E., 2015. Validation of three viablecell counting methods: Manual, semi-automated, and automated. Biotechnol. Rep. 7, 9 -16. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0115)
  23. Carvell, J.P., Dowd, J.E., 2006. On-line measurements and control of viable cell density in cell culture manufacturing processes using radio-frequency impedance. Cytotechnology 50 (1), 35. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0120)
  24. Ceasar, S.A., Rajan, V., Prykhozhij, S.V., Berman, J.N., Ignacimuthu, S., 2016. Insert, remove or replace: A highly advanced genome editing system using CRISPR/Cas9. Bba-Mol. Cell Res. 1863 (9), 2333 -2344. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0125)
  25. Challener, C.A., 2016. Fine tuning the focus on biopharma analytical studies. Biopharm. Int. 29 (2), 12 -17.
  26. Chen, F., Kou, T., Fan, L., Zhou, Y., Ye, Z., Zhao, L., Tan, W.-S., 2011. The combined e ff ect of sodium butyrate and low culture temperature on the production, sialylation, and biological activity of an antibody produced in CHO cells. Biotechnol. Bioprocess Eng. 16 (6), 1157 -1165. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0135)
  27. Chong, W.P., Goh, L.T., Reddy, S.G., Yusu fi , F.N., Lee, D.Y., Wong, N.S., Heng, C.K., Yap, M.G., Ho, Y.S., 2009. Metabolomics pro fi ling of extracellular metabolites in recombinant Chinese Hamster Ovary fed-batch culture. Rapid Commun. Mass Spectr. Int. J. Devoted Rapid Dissemin. Up-to-the-Minute Res. Mass Spectr. 23 (23), 3763 -3771. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0140)
  28. Chong, W.P., Yusu fi , F.N., Lee, D.-Y., Reddy, S.G., Wong, N.S., Heng, C.K., Yap, M.G., Ho, Y.S., 2011. Metabolomics-based identi fi cation of apoptosis-inducing metabolites in recombinant fed-batch CHO culture media. J. Biotechnol. 151 (2), 218 -224. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0145)
  29. Chotteau, V., Zhang, Y., Clincke, M.-F., 2014. Very high cell density in perfusion of CHO cells by ATF, TFF, wave bioreactor, and/or celltank technologies -impact of cell density and applications. In: Subramanian, G. (Ed.), Continuous Processing in Pharmaceutical Manufacturing. Wiley, New Jersey, pp. 339 -356. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0150)
  30. Chu, L., Robinson, D.K., 2001. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12 (2), 180 -187. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0155)
  31. Chung, A.W., Crispin, M., Pritchard, L., Robinson, H., Gorny, M.K., Yu, X., Bailey-Kellogg, C., Ackerman, M.E., Scanlan, C., Zolla-Pazner, S., Alter, G., 2014. Identi fi cation of antibody glycosylation structures that predict monoclonal antibody Fc-e ff ector function. AIDS. 28 (17), 2523 -2530. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0160)
  32. Clark, D.P., Pazdernik, N.J., 2013. Chapter e13 - Protein synthesis. In: Clark, D.P., http://refhub.elsevier.com/S0734-9750(2030049-5/rf0165)
  33. Clincke, M.-F., Mölleryd, C., Samani, P.K., Lindskog, E., Fäldt, E., Walsh, K., Chotteau, V., 2013. Very high density of Chinese hamster ovary cells in perfusion by alternating tangential fl ow or tangential fl ow fi ltration in WAVE bioreactor ™ -part II: Applications for antibody production and cryopreservation. Biotechnol. Prog. 29 (3), 768 -777. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0170)
  34. Colosimo, A., Goncz, K.K., Holmes, A.R., Kunzelmann, K., Novelli, G., Malone, R.W., Bennett, M.J., Gruenert, D.C., 2000. Transfer and expression of foreign genes in mammalian cells. Biotechniques 29 (2), 314. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0175)
  35. Constantin, C., Gradinaru, D., Manda, G., Neagu, M., Rusu, C., Ursaciuc, C., 2007. The respiratory burst evaluation by fl ow cytometry in normal elderly subjects. Cytom. Part B-Clin. Cy 72b (2), 143. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0180)
  36. Dang, L., Jia, L., Zhi, Y., Li, P., Zhao, T., Zhu, B., Lan, R., Hu, Y., Zhang, H., Sun, S., 2019. Mapping human N-linked glycoproteins and glycosylation sites using mass spectrometry. TrAC Trends in Anal. Chem. 114, 143 -150. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0185)
  37. Daya, S., Berns, K.I., 2008. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21 (4), 583 -593. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0190)
  38. Delafosse, L., Xu, P., Durocher, Y., 2016. Comparative study of polyethylenimines for transient gene expression in mammalian HEK293 and CHO cells. J. Biotechnol. 227, 103 -111. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0195)
  39. Deloitte, 2020. 2020 Global life sciences outlook. https://www2.deloitte.com/global/en/ pages/life-sciences-and-healthcare/articles/global-life-sciences-sector-outlook.html. https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/global-life-sciences-sector-outlook.html del-Val, I.J., Kontoravdi, C., Nagy, J.M., 2010. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol. Prog. 26 (6), 1505 -1527. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0205)
  40. Deo, Y.M., Mahadevan, M.D., Fuchs, R., 1996. Practical considerations in operation and scale-up of spin- fi lter based bioreactors for monoclonal antibody production. Biotechnol. Prog. 12 (1), 57 -64. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0210)
  41. Dimasi, L., 2011. Meeting increased demands on cell-based processes by using de fi ned media supplements. Bioprocess. J. 9 (8), 9. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0215)
  42. Doucet, C., Ernou, I., Zhang, Y., Llense, J.R., Begot, L., Holy, X., 2005. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J. Cell. Physiol. 205. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0220)
  43. Dumont, J., Euwart, D., Mei, B., Estes, S., Kshirsagar, R., 2015. Human cell lines for biopharmaceutical manufacturing: History, status, and future perspectives. Crit. Rev. Biotechnol. 18, 1 -13. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0225)
  44. Durocher, Y., Butler, M., 2009. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 20 (6), 700 -707. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0230)
  45. Ecker, D.M., Jones, S.D., Levine, H.L., 2015. The therapeutic monoclonal antibody market. Mabs 7 (1), 9 -14. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0235)
  46. Emwas, A.H., Roy, R., McKay, R.T., Tenori, L., Saccenti, E., Gowda, G.A.N., Raftery, D., Alahmari, F., Jaremko, L., Jaremko, M., Wishart, D.S., 2019. NMR spectroscopy for metabolomics research. Metabolites 9 (7). http://refhub.elsevier.com/S0734-9750(2030049-5/rf0240)
  47. European Medicines Agency, May 2011. ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities). In: ICH/Committee for medicinal products for human use. CHMP/ICH/425213/ 2011. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0245)
  48. Farzaneh, M., Hassani, S.N., Mozdziak, P., Baharvand, H., 2017. Avian embryos and related cell lines: A convenient platform for recombinant proteins and vaccine production. Biotechnol. J. 12 (5), 1600598. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0250)
  49. Filley, A.C., Henriquez, M., Dey, M., 2018. CART immunotherapy: Development success, and translation to malignant gliomas and other solid tumors. Front. Oncol. 8. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0260)
  50. Fisher, A.C., Lee, S.L., Harris, D.P., Buhse, L., Kozlowski, S., Yu, L., Kopcha, M., Woodcock, J., 2016. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's O ffi ce of Pharmaceutical Quality. Int. J. Pharm. 515 (1-2), 390 -402. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0265)
  51. Gagnon, M., Hiller, G., Luan, Y.-T., Kittredge, A., DeFelice, J., Drapeau, D., 2011. HighEnd pH-controlled delivery of glucose e ff ectively suppresses lactate accumulation in CHO Fed-batch cultures. Biotechnol. Bioeng. 108 (6), 1328 -1337. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0270)
  52. Gascon, P., 2012. Presently available biosimilars in hematology-oncology: G-CSF. Target. Oncol. 7 (1), 29 -34. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0275)
  53. Gaughan, C.L., 2016. The present state of the art in expression, production and characterization of monoclonal antibodies. Mol. Div. 20 (1), 255 -270. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0280)
  54. Gavin, W., Chen, L., Melican, D., Ziomek, C., Echelard, Y., Meade, H., 2008. Transgenic cloned goats and cows for the production of therapeutic proteins. In: Principles of Regenerative Medicine. Academic Press, pp. 168 -188. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0285)
  55. Geisse, S., 2009. Re fl ections on more than 10 years of TGE approaches. Protein Expr. Purif. 64 (2), 99 -107. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0290)
  56. Gilgunn, S., Bones, J., 2018. Challenges to industrial mAb bioprocessing -removal of host cell proteins in CHO cell bioprocesses. Curr. Opin. Chem. Eng. 22, 98 -106. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0295)
  57. Goh, J.B., Ng, S.K., 2018. Impact of host cell line choice on glycan pro fi le. Critic. Rev. Biotechnol. 38 (6), 851 -867. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0300)
  58. Grabowski, G.A., Golembo, M., Shaaltiel, Y., 2014. Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology. Mol. Genet. Metab. 112 (1), 1 -8. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0305)
  59. Grillberger, L., Kreil, T.R., Nasr, S., Reiter, M., 2009. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol. J. 4 (2), 186 -201. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0310)
  60. Grilo, A.L., Mantalaris, A., 2019. The increasingly human and pro fi table monoclonal antibody market. Trends Biotechnol. 37 (1), 9 -16. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0315)
  61. Gstraunthaler, G., Lindl, T., van der Valk, J., 2013. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology 65 (5), 791 -793. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0320)
  62. Gutiérrez-Granados, S., Cervera, L., Kamen, A.A., Gòdia, F., 2018. Advancements in http://refhub.elsevier.com/S0734-9750(2030049-5/rf0325) mammalian cell transient gene expression (TGE) technology for accelerated production of biologics. Critic. Rev. Biotechnol. 38 (6), 918 -940. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0325)
  63. Hamilton, S.R., Davidson, R.C., Sethuraman, N., Nett, J.H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T.A., Li, H., Choi, B.K., Hopkins, D., Wischnewski, H., Roser, J., Mitchell, T., Strawbridge, R.R., Hoopes, J., Wildt, S., Gerngross, T.U., 2006. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (5792), 1441 -1443. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0330)
  64. Hanna, E., Remuzat, C., Auquier, P., Toumi, M., 2017. Gene therapies development: Slow progress and promising prospect. J. Mark Access Health Policy 5 (1), 1265293. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0335)
  65. Hardee, C.L., Arevalo-Soliz, L.M., Hornstein, B.D., Zechiedrich, L., 2017. Advances in nonviral DNA vectors for gene therapy. Genes (Basel) 8 (2). http://refhub.elsevier.com/S0734-9750(2030049-5/rf0340)
  66. Hiller, G.W., Ovalle, A.M., Gagnon, M.P., Curran, M.L., Wang, W., 2017. Cell-controlled hybrid perfusion fed-batch CHO cell process provides signi fi cant productivity improvement over conventional fed-batch cultures. Biotechnol. Bioeng. 114 (7), 1438 -1447. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0345)
  67. Hossler, P., Racicot, C., Chumsae, C., McDermott, S., Cochran, K., 2017. Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation pro fi les. Biotechnol. Prog. 33 (2), 511 -522. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0350)
  68. Houdebine, L.-M., 2009. Production of pharmaceutical proteins by transgenic animals. Comp. Immunol. Microbiol. Infect. Dis. 32 (2), 107 -121. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0355)
  69. Huang, Y.M., Hu, W., Rustandi, E., Chang, K., Yusuf-Makagiansar, H., Ryll, T., 2010. Maximizing productivity of CHO cell-based fed-batch culture using chemically defi ned media conditions and typical manufacturing equipment. Biotechnol. Prog. 26 (5), 1400 -1410. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0360)
  70. Hunter, M., Yuan, P., Vavilala, D., Fox, M., 2019. Optimization of protein expression in mammalian cells. Curr. Protoc. Protein Sci. 95 (1), e77. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0365)
  71. Ikegami, T., 2019. Hydrophilic interaction chromatography for the analysis of biopharmaceutical drugs and therapeutic peptides: A review based on the separation characteristics of the hydrophilic interaction chromatography phases. J. Separ. Sci. 42 (1), 130 -213. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0370)
  72. Ivarsson, M., Villiger, T.K., Morbidelli, M., Soos, M., 2014. Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation. J. Biotechnol. 188, 88 -96. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0375)
  73. Jacquemart, R., Vandersluis, M., Zhao, M., Sukhija, K., Sidhu, N., Stout, J., 2016. A singleuse strategy to enable manufacturing of a ff ordable biologics. Computat. Struct. Biotechnol. J. 14, 309 -318. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0380)
  74. Jochems, C.E., Van Der Valk, J.B., Sta fl eu, F.R., Baumans, V., 2002. The use of fetal bovine serum: Ethical or scienti fi c problem? ATLA-NOTTINGHAM 30 (2), 219 -228. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0385)
  75. Jordan, M., Wurm, F., 2004. Transfection of adherent and suspended cells by calcium phosphate. Methods 33 (2), 136 -143. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0390)
  76. Kaltashov, I.A., Bobst, C.E., Abzalimov, R.R., Berkowitz, S.A., Houde, D., 2010. Conformation and dynamics of biopharmaceuticals: Transition of mass spectrometrybased tools from academe to industry. J. Am. Soc. Mass Spectr. 21 (3), 323 -337. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0395)
  77. Karnieli, O., Friedner, O.M., Allickson, J.G., Zhang, N., Jung, S., Fiorentini, D., Abraham, E., Eaker, S.S., Yong, t.K., Chan, A., Gri ffi ths, S., Wehn, A.K., Oh, S., Karnieli, O., 2017. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy 19 (2), 155 -169. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0400)
  78. Karst, D.J., Steinebach, F., Soos, M., Morbidelli, M., 2017. Process performance and product quality in an integrated continuous antibody production process. Biotechnol. Bioeng. 114 (2), 298 -307. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0410)
  79. Kesik-Brodacka, M., 2018. Progress in biopharmaceutical development. Biotechnol. Appl. Biochem. 65 (3), 306 -322. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0415)
  80. Kessler, M., Goldsmith, D., Schellekens, H., 2006. Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 21 (Suppl. 5), v9 -12. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0420)
  81. Kim, I., 2013. A brief overview of cell therapy and its product. J. Korean Assoc. Oral Maxillofac. Surg. 39 (5), 201 -202. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0425)
  82. Kim, T.K., Eberwine, J.H., 2010. Mammalian cell transfection: The present and the future. Anal. Bioanal. Chem. 397 (8), 3173 -3178. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0430)
  83. Kim, S.J., Park, Y., Hong, H.J., 2005. Antibody engineering for the development of therapeutic antibodies. Mol. Cells 20 (1), 17 -29. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0435)
  84. Kim, M., O'Callaghan, P.M., Droms, K.A., James, D.C., 2011. A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies. Biotechnol. Bioeng. 108 (10), 2434 -2446. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0440)
  85. Kim, Y.J., Baek, E., Lee, J.S., Lee, G.M., 2013. Autophagy and its implication in Chinese hamster ovary cell culture. Biotechnol. Lett. 35 (11), 1753 -1763. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0445)
  86. Kiss, R., Fizil, A., Szantay, C., 2018. What NMR can do in the biopharmaceutical industry. J. Pharmaceut. Biomed. 147, 367 -377. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0450)
  87. Klutz, S., Magnus, J., Lobedann, M., Schwan, P., Maiser, B., Niklas, J., Temming, M., Schembecker, G., 2015. Developing the biofacility of the future based on continuous processing and single-use technology. J. Biotechnol. 213 (Supplement C), 120 -130. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0455)
  88. Kost, T.A., Condreay, J.P., Jarvis, D.L., 2005. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 23 (5), 567 -575. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0460)
  89. Krampe, B., Al-Rubeai, M., 2010. Cell death in mammalian cell culture: Molecular mechanisms and cell line engineering strategies. Cytotechnology 62 (3), 175 -188. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0465)
  90. Kuriakose, A., Chirmule, N., Nair, P., 2016. Immunogenicity of biotherapeutics: Causes and association with posttranslational modi fi cations. J. Immunol. Res. 2016, 1298473. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0470)
  91. Lalani, J., Misra, A., 2011. Gene delivery using chemical methods. In: Challenges in delivery of therapeutic genomics and proteomics. Elsevier, pp. 127 -206. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0475)
  92. Li, J., Wong, C.L., Vijayasankaran, N., Hudson, T., Amanullah, A., 2012. Feeding lactate for CHO cell culture processes: impact on culture metabolism and performance. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0485)
  93. Li, T., DiLillo, D.J., Bournazos, S., Giddens, J.P., Ravetch, J.V., Wang, L.-X., 2017. Modulating IgG e ff ector function by Fc glycan engineering. Proc. Natl Acad. Sci. 114 (13), 3485 -3490. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0490)
  94. Linnebjerg, H., Lam, E.C.Q., Seger, M.E., Coutant, D., Chua, L., Chong, C.L., Ferreira, M.M., Soon, D., Zhang, X., 2015. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU-and US-approved versions of Lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies. Diab. Care 38 (12), 2226 -2233. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0495)
  95. Longo, P.A., Kavran, J.M., Kim, M.-S., Leahy, D.J., 2013. Generating mammalian stable cell lines by electroporation. In: Methods in Enzymology. Elsevier, pp. 209 -226. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0500)
  96. Lu, F., Toh, P.C., Burnett, I., Li, F., Hudson, T., Amanullah, A., Li, J., 2013. Automated dynamic fed-batch process and media optimization for high productivity cell culture process development. Biotechnol. Bioeng. 110 (1), 191 -205. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0505)
  97. Luft, C., Ketteler, R., 2015. Electroporation knows no boundaries: The use of electrostimulation for siRNA delivery in cells and tissues. J. Biomol. Screen. 20 (8), 932 -942. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0510)
  98. Lund, A.M., Kildegaard, H.F., Petersen, M.B.K., Rank, J., Hansen, B.G., Andersen, M.R., Mortensen, U.H., 2014. A versatile system for USER cloning-based assembly of expression vectors for mammalian cell engineering. PLoS One 9 (5). http://refhub.elsevier.com/S0734-9750(2030049-5/rf0515)
  99. Lundin, K.E., Gissberg, O., Smith, C.I., 2015. Oligonucleotide therapies: The past and the present. Hum. Gene Ther. 26 (8), 475 -485. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0520)
  100. Lundstrom, K., 2018. Viral vectors in gene therapy. Diseases 6 (2). http://refhub.elsevier.com/S0734-9750(2030049-5/rf0525)
  101. Makrides, S.C., 1999. Components of vectors for gene transfer and expression in mammalian cells. Protein Expr. Purif. 17 (2), 183 -202. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0530)
  102. Marin, M., Güris, D., Chaves, S.S., Schmid, S., Seward, J.F., 2007. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 22 (56), 1 -40. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0535)
  103. McCamish, M., Woollett, G., 2012. The rise of the biosimilar. Expert Rev. Clin. Phar. 5 (6), 597 -599.
  104. McCracken, N., Kowle, R., Ouyang, A., 2014. Control of galactosylated glycoforms distribution in cell culture system. Biotechnol. Prog. 30. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0545)
  105. Mimee, M., Citorik, R.J., Lu, T.K., 2016. Microbiome therapeutics - Advances and challenges. Adv. Drug Deliv. Rev. 105 (Pt A), 44 -54. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0550)
  106. Mimura, Y., Lund, J., Church, S., Dong, S., Li, J., Goodall, M., Je ff eris, R., 2001. Butyrate increases production of human chimeric IgG in CHO-K1 cells whilst maintaining function and glycoform pro fi le. J. Immunol. Methods 247 (1), 205 -216. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0555)
  107. Monie, A., Hung, C.-F., Roden, R., Wu, T.C., 2008. Cervarix ™ : a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biol. Targets Ther. 2 (1), 107. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0560)
  108. Moorkens, E., Meuwissen, N., Huys, I., Declerck, P., Vulto, A.G., Simoens, S., 2017. The market of biopharmaceutical medicines: A snapshot of a diverse industrial landscape. Front. Pharmacol. 8, 314. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0565)
  109. Moran, N., 2013. Mouse Platforms Jostle for Slice of Humanized Antibody Market. Nature Publishing Group. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0570)
  110. Morgan, J.F., Morton, H.J., Parker, R.C., 1950. Nutrition of animal cells in tissue culture; initial studies on a synthetic medium. Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. (New York, N.Y.) 73 (1), 1 -8. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0575)
  111. Möricke, R., Rettig, K., Bethke, T.D., 2011. Use of recombinant human parathyroid hormone (1 -84) in patients with postmenopausal osteoporosis. Clin. Drug Invest. 31 (2), 87 -99. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0580)
  112. Morris, A.E., Schmid, J., 2000. E ff ects of insulin and longR3 on serum-free chinese hamster ovary cell cultures expressing two recombinant proteins. Biotechnol. Prog. 16 (5), 693 -697. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0585)
  113. Mostaghaci, B., Loretz, B., Lehr, C.-M., 2016. Calcium phosphate system for gene delivery: Historical background and emerging opportunities. Curr. Pharmaceut. Design 22 (11), 1529 -1533. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0590)
  114. Mulukutla, B.C., Kale, J., Kalomeris, T., Jacobs, M., Hiller, G.W., 2017. Identi fi cation and control of novel growth inhibitors in fed-batch cultures of Chinese hamster ovary cells. Biotechnol. Bioeng. 114 (8), 1779 -1790. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0595)
  115. Nayerossadat, N., Maedeh, T., Ali, P.A., 2012. Viral and nonviral delivery systems for gene delivery. Adv. Biomed. Res. 1. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0600)
  116. Nienow, A.W., 2006. Reactor engineering in large scale animal cell culture. Cytotechnology 50 (1), 9. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0605)
  117. O'Flaherty, R., Trbojevic-Akmacic, I., Greville, G., Rudd, P.M., Lauc, G., 2017. The sweet spot for biologics: Recent advances in characterization of biotherapeutic glycoproteins. Expert Rev. Proteomics 1 -17. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0610)
  118. Oishi, I., Yoshii, K., Miyahara, D., Tagami, T., 2018. E ffi cient production of human interferon beta in the white of eggs from ovalbumin gene-targeted hens. Scient. Rep. 8 (1), 10203. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0615)
  119. Overton, T.W., 2014. Recombinant protein production in bacterial hosts. Drug Discov. today 19 (5), 590 -601. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0620)
  120. Peschke, B., Keller, C.W., Weber, P., Quast, I., Lünemann, J.D., 2017. Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol. 8, 646. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0630)
  121. Pineda, C., Castaneda Hernandez, G., Jacobs, I.A., Alvarez, D.F., Carini, C., 2016. Assessing the immunogenicity of biopharmaceuticals. BioDrugs 30 (3), 195 -206. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0640)
  122. Quaranta, A., Sroka-Bartnicka, A., Tengstrand, E., Thorsen, G., 2016. N-Glycan pro fi le analysis of transferrin using a micro fl uidic compact disc and MALDI-MS. Anal. Bioanal. Chem. 408 (17), 4765 -4776. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0645)
  123. Rader, R.A., 2008. (Re)de fi ning biopharmaceutical. Nat. Biotechnol. 26 (7), 743 -751. Ramm, R., Hartmann, T., Tudorache, I., Haverich, A., Hil fi ker, A., 2015. No evidence for alphaGal epitope transfer from media containing FCS onto human endothelial cells in http://refhub.elsevier.com/S0734-9750(2030049-5/rf0655) culture. Xenotransplantation 22 (5), 345 -355. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0655)
  124. Ramsland, P.A., Hutchinson, A.T., Carter, P.J., 2015. Therapeutic antibodies: Discovery, design and deployment. Mol. Immunol. 67 (2), 1 -3. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0660)
  125. Rathore, A.S., Bhambure, R., Ghare, V., 2010. Process analytical technology (PAT) for biopharmaceutical products. Anal. Bioanal. Chem. 398 (1), 137 -154. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0665)
  126. Rathore, A.S., Agarwal, H., Sharma, A.K., Pathak, M., Muthukumar, S., 2015. Continuous processing for production of biopharmaceuticals. Prep. Biochem. Biotech. 45 (8), 836 -849. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0670)
  127. Rattu, M.A., Shah, N., Lee, J.M., Pham, A.Q., Marzella, N., 2013. Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. Pharm. Therap. 38 (12), 732. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0675)
  128. Raymond, C., Tom, R., Perret, S., Moussouami, P., L ' Abbé, D., St-Laurent, G., Durocher, Y., 2011. A simpli fi ed polyethylenimine-mediated transfection process for large-scale and high-throughput applications. Methods 55 (1), 44 -51. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0680)
  129. Read, E., Park, J., Shah, R., Riley, B., Brorson, K., Rathore, A., 2010. Process analytical technology (PAT) for biopharmaceutical products: Part I. Concepts and applications. Biotechnol. Bioeng. 105 (2), 276 -284. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0685)
  130. Ritacco, F.V., Wu, Y., Khetan, A., 2018. Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies. Biotechnol. Prog. 34 (6), 1407 -1426. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0690)
  131. Rozov, S.M., Permyakova, N.V., Deineko, E.V., 2018. Main strategies of plant expression system glycoengineering for producing humanized recombinant pharmaceutical proteins. Biochemistry (Moscow) 83 (3), 215 -232. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0695)
  132. Rudewicz, P.J., 2013. Simultaneous Lc-Ms quantitation and metabolite identi fi cation in drug metabolism and pharmacokinetics. In: Handbook of Lc-Ms Bioanalysis: Best Practices, Experimental Protocols, and Regulations, pp. 417 -427. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0700)
  133. Ryu, J.K., Kim, H.S., Nam, D.H., 2012. Current status and perspectives of biopharmaceutical drugs. Biotechnol. Bioprocess Eng. 17 (5), 900 -911. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0705)
  134. Sahdev, S., Khattar, S.K., Saini, K.S., 2008. Production of active eukaryotic proteins through bacterial expression systems: A review of the existing biotechnology strategies. Mol. Cell. Biochem. 307 (1), 249 -264. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0710)
  135. Sandra, K., Vandenheede, I., Sandra, P., 2014. Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization. J. Chromatogr. A 1335, 81 -103. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0715)
  136. Sandra, K., Steenbeke, M., Vandenheede, I., Vanhoenacker, G., Sandra, P., 2017. The versatility of heart-cutting and comprehensive two-dimensional liquid chromatography in monoclonal antibody clone selection. J. Chromatogr. A 1523, 283 -292. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0720)
  137. Sangshetti, J.N., Deshpande, M., Zaheer, Z., Shinde, D.B., Arote, R., 2017. Quality by design approach: Regulatory need. Arab. J. Chem. 10, S3412 -S3425. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0725)
  138. Sauve, S., Gingras, G., Aubin, Y., 2008. Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fi ngerprinting: Demonstration on recombinant human granulocyte macrophage-colony stimulation factor. Biomol. NMR Assign. 2 (1), 5 -7. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0730)
  139. Schaub, J., Clemens, C., Schorn, P., Hildebrandt, T., Rust, W., Mennerich, D., Kaufmann, H., Schulz, T.W., 2010. CHO gene expression pro fi ling in biopharmaceutical process analysis and design. Biotechnol. Bioeng. 105 (2), 431 -438. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0735)
  140. Schmittgen, T.D., Zakrajsek, B.A., Mills, A.G., Gorn, V., Singer, M.J., Reed, M.W., 2000. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 285 (2), 194 -204. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0740)
  141. Selvarasu, S., Ho, Y.S., Chong, W.P., Wong, N.S., Yusu fi , F.N., Lee, Y.Y., Yap, M.G., Lee, D.Y., 2012. Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO cell culture. Biotechnol. Bioeng. 109 (6), 1415 -1429. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0745)
  142. Sha, S., Agarabi, C., Brorson, K., Lee, D.Y., Yoon, S., 2016. N-glycosylation design and control of therapeutic monoclonal antibodies. Trends Biotechnol. 34 (10), 835 -846. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0750)
  143. Shen, A.Y., Van de Goor, J., Zheng, L., Reyes, A.E., Krummen, L.A., 2005. Recombinant DNA technology and cell line development. In: Cell Culture Technology for Pharmaceutical and Cell-Based Therapies. CRC Press, pp. 33 -58. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0755)
  144. Steger, K., Brady, J., Wang, W., Duskin, M., Donato, K., Peshwa, M., 2015. CHO-S antibody titers > 1 gram/liter using fl ow electroporation-mediated transient gene expression followed by rapid migration to high-yield stable cell lines. J. Biomol. Screen. 20 (4), 545 -551. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0760)
  145. Stephanopoulos, N., Francis, M.B., 2011. Choosing an e ff ective protein bioconjugation strategy. Nat. Chem. Biol. 7 (12), 876 -884. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0765)
  146. Stockmann, H., O'Flaherty, R., Adamczyk, B., Saldova, R., Rudd, P.M., 2015. Automated, high-throughput serum glycopro fi ling platform. Integr. Biol. (Camb.) 7 (9), 1026 -1032. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0770)
  147. Strober, W., 2015. Trypan Blue Exclusion Test of Cell Viability. Curr. Protoc. Immunol. 111, A3.B.1 -A3.B.3. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0780)
  148. Takagi, Y., Kikuchi, T., Wada, R., Omasa, T., 2017. The enhancement of antibody concentration and achievement of high cell density CHO cell cultivation by adding nucleoside. Cytotechnology 69 (3), 511 -521. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0785)
  149. Tandon, N., Thakkar, K.N., LaGory, E.L., Liu, Y., Giaccia, A.J., 2018. Generation of stable expression mammalian cell lines using lentivirus. Bio-Protocol 8 (21). http://refhub.elsevier.com/S0734-9750(2030049-5/rf0790)
  150. Tayi, V.S., Butler, M., 2015. Isolation and quanti fi cation of N-glycans from immunoglobulin G antibodies for quantitative glycosylation analysis. pp. 2015. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0795)
  151. Tayi, V., Butler, M., 2018. Solid-phase enzymatic remodeling produces high yields of single glycoform antibodies. Biotechnol. J. 13 (4), e1700381. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0800)
  152. Tekkatte, C., Gunasingh, G.P., Cherian, K., Sankaranarayanan, K., 2011. ' Humanized ' stem cell culture techniques: the animal serum controversy. Stem Cells Int. 2011. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0810)
  153. Thomann, M., Reckermann, K., Reusch, D., Prasser, J., Tejada, M.L., 2016. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic http://refhub.elsevier.com/S0734-9750(2030049-5/rf0815) antibodies. Mol. Immunol. 73, 69 -75. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0815)
  154. Thompson, B.C., Segarra, C.R.J., Mozley, O.L., Daramola, O., Field, R., Levison, P.R., James, D.C., 2012. Cell line speci fi c control of polyethylenimine-mediated transient transfection optimized with ' Design of experiments ' methodology. Biotechnol. Prog. 28 (1), 179 -187. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0820)
  155. Thompson, J.H., Chung, W.K., Zhu, M., Tie, L., Lu, Y., Aboulaich, N., Strouse, R., Mo, W.D., 2014. Improved detection of host cell proteins (HCPs) in a mammalian cellderived antibody drug using liquid chromatography/mass spectrometry in conjunction with an HCP-enrichment strategy. Rapid Commun. Mass Spectr. RCM 28 (8), 855 -860. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0825)
  156. Tintó, A., Gabernet, C., Vives, J., Prats, E., Cairó, J.J., Cornudella, L.s., Gòdia, F., 2002. The protection of hybridoma cells from apoptosis by caspase inhibition allows culture recovery when exposed to non-inducing conditions. J. Biotechnol. 95 (3), 205 -214. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0830)
  157. Tran, K., Gurramkonda, C., Cooper, M.A., Pilli, M., Taris, J.E., Selock, N., Han, T.C., Tolosa, M., Zuber, A., Penalber-Johnstone, C., Dinkins, C., Pezeshk, N., Kostov, Y., Frey, D.D., Tolosa, L., Wood, D.W., Rao, G., 2018. Cell-free production of a therapeutic protein: Expression, puri fi cation, and characterization of recombinant streptokinase using a CHO lysate. Biotechnol. Bioeng. 115 (1), 92 -102. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0835)
  158. Tscheliessnig, A.L., Konrath, J., Bates, R., Jungbauer, A., 2013. Host cell protein analysis in therapeutic protein bioprocessing - methods and applications. Biotechnol. J. 8 (6), 655 -670. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0025)
  159. Tsuchikama, K., An, Z.Q., 2018. Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell 9 (1), 33 -46. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0840)
  160. Urbano, P., Urbano, F., 2007. Nanobacteria: Facts or fancies? PLoS Pathog. 3 (5), e55. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0850)
  161. Valk, J., Brunner, D., Smet, K., Fex Svenningsen, A., Honegger, P., Knudsen, L.E., 2010. Optimization of chemically de fi ned cell culture media -replacing fetal bovine serum in mammalian in vitro methods. Toxicol. In Vitro 24. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0855)
  162. Van Landuyt, L., Lonigro, C., Meuris, L., Callewaert, N., 2018. Customized protein glycosylation to improve biopharmaceutical function and targeting. Curr. Opin. Biotechnol. 60, 17 -28. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0860)
  163. Van, M.R., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E., Hart't, B., Poelmans, S., Bontinck, L., 2015. The preclinical pharmacology of the high a ffi nity anti-IL-6R Nanobody ® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res. Ther. 17 (1), 135. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0865)
  164. Vanderlaan, M., Zhu-Shimoni, J., Lin, S., Gunawan, F., Waerner, T., Van Cott, K.E., 2018. Experience with host cell protein impurities in biopharmaceuticals. Biotechnol. Prog. 34 (4), 828 -837. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0870)
  165. Varadi, C., Lew, C., Guttman, A., 2014. Rapid magnetic bead based sample preparation for automated and high throughput N-glycan analysis of therapeutic antibodies. Anal. Chem. 86 (12), 5682 -5687. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0875)
  166. Vlahos, C.J., Coghlan, M.J., 2005. Next-generation therapeutics - Chemistry and biology at the innovation interface. Curr. Opin. Chem. Biol. 9 (4), 333 -335. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0880)
  167. Voisard, D., Meuwly, F., Ru ffi eux, P.A., Baer, G., Kadouri, A., 2003. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol. Bioeng. 82 (7), 751 -765. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0885)
  168. Waller, E.K., 2007. The role of sargramostim (rhGM-CSF) as immunotherapy. The Oncologist 12 (Supplement 2), 22 -26. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0890)
  169. Walsh, G., 2010. Post-translational modi fi cations of protein biopharmaceuticals. Drug Discov. Today 15 (17-18), 773 -780. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0895)
  170. Walsh, G., 2014. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0900)
  171. Walsh, C.T., Garneau-Tsodikova, S., Gatto Jr., G.J., 2005. Protein posttranslational modi fi cations: The chemistry of proteome diversi fi cations. Angew. Chem. Int. Edn 44 (45), 7342 -7372. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0905)
  172. Wang, L.-X., Amin, M.N., 2014. Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions. Chem. Biol. 21 (1), 51 -66. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0910)
  173. Wang, L., Zheng, W.F., Liu, S.Q., Li, B., Jiang, X.Y., 2019. Delivery of CRISPR/Cas9 by novel strategies for gene therapy. Chembiochem 20 (5), 634 -643. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0915)
  174. Wishart, D.S., 2013. Characterization of biopharmaceuticals by NMR spectroscopy. TracTrend Anal. Chem. 48, 96 -111. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0920)
  175. Wong, A.W., Baginski, T.K., Reilly, D.E., 2010. Enhancement of DNA uptake in FUT8deleted CHO cells for transient production of afucosylated antibodies. Biotechnol. Bioeng. 106 (5), 751 -763. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0925)
  176. Wurm, F.M., 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22 (11), 1393. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0930)
  177. Yamane-Ohnuki, N., Kinoshita, S., Inoue-Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., Shitara, K., Satoh, M., 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87 (5), 614 -622. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0945)
  178. Yang, Z., Xiong, H.-R., 2012. Culture conditions and types of growth media for mammalian cells. In: Biomedical Tissue Culture. IntechOpen. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0950)
  179. Yu, L.X., Woodcock, J., 2015. FDA pharmaceutical quality oversight. Int. J. Pharm. 491 (1-2), 2 -7.
  180. Yu, L.X., Amidon, G., Khan, M.A., Hoag, S.W., Polli, J., Raju, G.K., Woodcock, J., 2014. Understanding pharmaceutical quality by design. Am. Assoc. Pharm. Scient. J. 16 (4), 771 -783. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0965)
  181. Yusibov, V., Kushnir, N., Streat fi eld, S.J., 2016. Antibody production in plants and green algae. Annu. Rev. Plant Biol. 67 (1), 669 -701. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0970)
  182. Zanghi, J.A., Renner, W.A., Bailey, J.E., Fussenegger, M., 2000. The growth factor inhibitor suramin reduces apoptosis and cell aggregation in protein-free CHO cell batch cultures. Biotechnol. Prog. 16 (3), 319 -325. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0975)
  183. Zhang, L., Luo, S., Zhang, B., 2016. Glycan analysis of therapeutic glycoproteins. mAbs 8 http://refhub.elsevier.com/S0734-9750(2030049-5/rf0980)
  184. Zhong, M., 2018. Extractable and leachable testing in pharmaceutical analysis. Pharm. Anal. Acta 9 (6), 2. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0985)
  185. Zion Market Research, A., 2018. Monoclonal antibody therapeutics market by application (cancer, autoimmune diseases, infection, hematological diseases, and others). In: By Source and By End Users: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023, pp. 110. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0990)
  186. Zydney, A.L., 2016. Continuous downstream processing for high value biological products: A review. Biotechnol. Bioeng. 113 (3), 465 -475. http://refhub.elsevier.com/S0734-9750(2030049-5/rf0995)

Cited by

Sorted by citations

Authors
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M.
Venue
Biotechnology Advances
Publisher
Elsevier BV
Published
2020-11
Volume
43
Pages
107552
ISSN
0734-9750
DOI
10.1016/j.biotechadv.2020.107552
Cited by
232
References
11
Language
en
Licence
Funders
  • Enterprise Ireland
  • Science Foundation Ireland

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review